Entry of SARS-CoV-2 into host cells is mediated by interaction between spike proteins and ACE2. To aid the study of virus-receptor interactions and the development of therapies for COVID-19, we have developed a stable HEK-derived cell line that expresses ACE2 under the CMV promoter. The cell line has been confirmed to express ACE2 at consistently high levels across multiple passages and is efficiently transduced by SARS-CoV-2 pseudovirus generated using Lenti-X SARS-CoV-2 Packaging Single Shots.
Entry of SARS-CoV-2 into host cells is mediated by interaction between spike proteins and ACE2. To aid the study of virus-receptor interactions and the development of therapies for COVID-19, we have developed a stable HEK-derived cell line that expresses ACE2 under the CMV promoter. The cell line has been confirmed to express ACE2 at consistently high levels across multiple passages and is efficiently transduced by SARS-CoV-2 pseudovirus generated using Lenti-X SARS-CoV-2 Packaging Single Shots.
ACE2 is a zinc-containing metalloenzyme located on the surface of endothelial and other cell types. This transmembrane protein converts angiotensin I to angiotensin 1–9, a 9-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1–7, which then acts as a beneficial vasodilator and anti-proliferation agent.
The Human ACE2 293T Cell Line was engineered by transduction of an HEK cell line with lentivirus encoding human ACE2. The cell line was subcloned for high expression of ACE2, and confirmed via RT-qPCR.
More Less
